Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia
•23 chronic insomnia patients treated with ZLT-101, Zelira’s proprietary and patented medicinalcannabis formulation, demonstrated statistically significant improvement in Insomnia SeverityIndex scores compared to placebo •ZLT-101 therapy was well tolerated, with no serious adverse events reported •Positive trial results an important milestone for Zelira •Poised to launch world’s first clinically validated medicinal cannabis product for insomnia in 2020 •Expands Zelira’s product portfolio alongside the HOPETM product range
